49 results on '"Wildemberg LE"'
Search Results
2. The ubiquitin-specific peptidase 8 (USP8) gene is frequently mutated in adenomas causing Cushing's disease.
- Author
-
Perez-Rivas, L, primary, Theodoropoulou, M, additional, Ferraù, F, additional, Nusser, C, additional, Kawaguchi, K, additional, Stratakis, CA, additional, Rueda Faucz, F, additional, Wildemberg, LE, additional, Assiè, G, additional, Beschorner, R, additional, Dimopoulou, C, additional, Buchfelder, M, additional, Popovic, V, additional, Berr, C, additional, Toth, MI, additional, Ardisasmita, AI, additional, Honegger, J, additional, Bertherat, J, additional, Gadelha, M, additional, Beuschlein, F, additional, Stalla, G, additional, Komada, M, additional, Korbonits, M, additional, and Reincke, M, additional
- Published
- 2015
- Full Text
- View/download PDF
3. Pituitary gigantism due to a novel AIP germline splice-site variant.
- Author
-
Lamback E, Miranda RL, Chimelli L, Andreiuolo F, Kasuki L, Wildemberg LE, and Gadelha MR
- Abstract
Pituitary gigantism is a rare pediatric disorder caused by excess growth hormone (GH) secretion. In almost 50% of cases, a genetic cause can be identified, with pathogenic variants in the aryl hydrocarbon receptor-interacting protein ( AIP ) gene being the most common. We present a case of an 11-year-old boy who exhibited progressive vision loss, associated with accelerated linear growth, and weight gain. On physical examination, he had enlarged hands, right eye amaurosis, and was already above his target height. Increased GH and IGF-I concentrations confirmed the diagnosis of pituitary gigantism. Magnetic resonance imaging showed a giant sellar lesion with supra- and para-sellar extensions. He underwent two surgeries which did not achieve a cure or visual improvement. Histopathological analysis revealed a sparsely granulated tumor, negative for somatostatin receptor type 2 (SST2) and an immunoreactivity score of 6 for somatostatin receptor type 5 (SST5). Our published artificial intelligence prediction model predicted an 83% chance of not responding to first-generation somatostatin receptor ligands. Pasireotide was therefore prescribed, and afterward cabergoline was added on. IGF-I concentrations decreased but did not normalize. We discovered a novel germline single nucleotide variant in the splicing donor region of intron 2 of the AIP gene (NM_003977.4:c.279+1 G>A), classified as likely pathogenic according to the American College of Medical Genetics and Genomics guidelines., Competing Interests: EL has received speaker fees from Ipsen. LK has received speaker fees from Ipsen and Novo Nordisk. LEW has received speaker fees from Ipsen and Recordati, and is sub-investigator in clinical trials from Recordati and Crinetics. MRG has received speaker fees from Recordati, Ipsen and Novo Nordisk, has served as a member of the advisory board of Recordati, Ipsen, Novo Nordisk and Crinetics, and as principal investigator in clinical trials from Recordati and Crinetics. The other authors report no conflicts of interest., (© the author(s).)
- Published
- 2024
- Full Text
- View/download PDF
4. Epigenetic Control of Adamantinomatous Craniopharyngiomas.
- Author
-
Marrero-Gutiérrez J, Bueno AC, Martins CS, Coeli-Lacchini FB, Silva-Júnior RMP, Marques Gonçalves GH, Ozaki JGO, de Almeida E Silva DC, Wildemberg LE, da Silva Antunes XL, Dos Santos AC, Machado HR, Santos MV, Moreira AC, Gadelha MR, Vêncio RZN, Antonini SRR, and de Castro M
- Subjects
- Humans, Male, Female, Adolescent, Adult, Child, Middle Aged, Young Adult, Child, Preschool, Aged, Mutation, CpG Islands genetics, Gene Expression Regulation, Neoplastic, Craniopharyngioma genetics, Craniopharyngioma pathology, DNA Methylation, Pituitary Neoplasms genetics, Pituitary Neoplasms pathology, Epigenesis, Genetic, beta Catenin genetics, beta Catenin metabolism
- Abstract
Introduction: Studies addressing the methylation pattern in adamantinomatous craniopharyngioma (ACP) are lacking., Objective: To identify methylation signatures in ACPs regarding clinical presentation and outcome., Methods: Clinical and pathology data were collected from 35 patients with ACP (54% male; 18.1 years [2-68]). CTNNB1 mutations and methylation profile (MethylationEPIC/Array-Illumina) were analyzed in tumoral DNA. Unsupervised machine learning analysis of this comprehensive methylome sample was achieved using hierarchical clustering and multidimensional scaling. Statistical associations between clusters and clinical features were achieved using the Fisher test and global biological process interpretations were aided by Gene Ontology enrichment analyses., Results: Two clusters were revealed consistently by all unsupervised methods (ACP-1: n = 18; ACP-2: n = 17) with strong bootstrap statistical support. ACP-2 was enriched by CTNNB1 mutations (100% vs 56%, P = .0006), hypomethylated in CpG island, non-CpG Island sites, and globally (P < .001), and associated with greater tumor size (24.1 vs 9.5 cm3, P = .04). Enrichment analysis highlighted pathways on signaling transduction, transmembrane receptor, development of anatomical structures, cell adhesion, cytoskeleton organization, and cytokine binding, and cell type-specific biological processes as regulation of oligodendrocytes, keratinocyte, and epithelial cells differentiation., Conclusion: Two clusters of patients with ACP were consistently revealed by unsupervised machine learning methods, with one of them significantly hypomethylated, enriched by CTNNB1 mutated ACPs, and associated with increased tumor size. Enrichment analysis reinforced pathways involved in tumor proliferation and in cell-specific tumoral microenvironment., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
5. Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine.
- Author
-
Wildemberg LE, Fialho C, and Gadelha MR
- Subjects
- Humans, Receptors, Somatostatin agonists, Acromegaly drug therapy
- Abstract
Injectable first-generation somatostatin receptor ligands (fg-SRLs) are the standard of care of medical treatment for acromegaly. While fg-SRLs control acromegaly in up to 50 % of patients, they may lead to bothersome injection pain and site reactions. Paltusotine is an investigational, highly selective somatostatin receptor subtype 2 agonist, which is administered orally once a day. To date, phase 2 and 3 clinical trials suggest paltusotine treatment can achieve biochemical and symptom control in acromegaly, with a safety profile comparable to those of the fg-SRLs. Since paltusotine is a once-daily oral drug, it may represent a future treatment option for addressing patient preference or improving quality of life., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
6. Alternative Approach to BIPSS in the Differential Diagnosis of ACTH-Dependent Cushing Syndrome.
- Author
-
Gadelha M and Wildemberg LE
- Subjects
- Humans, Diagnosis, Differential, Adrenocorticotropic Hormone blood, Cushing Syndrome diagnosis, Cushing Syndrome blood
- Published
- 2024
- Full Text
- View/download PDF
7. GH and prolactin co-secreting adenomas: it is time for a definition.
- Author
-
Wildemberg LE and Gadelha MR
- Published
- 2024
- Full Text
- View/download PDF
8. Evaluation of bone mineral density, microarchitecture, and detection of fractures on young patients living with human immunodeficiency virus: when and how to screen?
- Author
-
Gehrke B, Farias MLF, Wildemberg LE, Ferraiuoli GI, Ribeiro V, Bosgnoli R, Paranhos Neto FP, de Mendonça LMC, Madeira M, and Coelho MCA
- Subjects
- Humans, Male, Female, Adult, Bone Density, HIV, Quality of Life, Absorptiometry, Photon, Radius, Osteoporotic Fractures diagnostic imaging, Osteoporotic Fractures epidemiology, Osteoporotic Fractures etiology, Spinal Fractures, HIV Infections complications
- Abstract
Purpose: People living with the human immunodeficiency virus (PLWH) developed higher life expectancy along with chronic bone disease over the past years. Our purpose is to evaluate bone mineral density, bone microarchitecture and fractures in young PLWH and understand the disease's contribution to bone derangements and fracture risk., Methods: Eighty-one HIV-infected and 54 control young (20-50 years) male and female subjects were enrolled in this study. Methods for patient evaluation included DXA-VFA (dual energy X-rays and vertebral fracture assessment), HR-pQCT (high resolution peripheral quantitative computed tomography), biochemistry and FRAX., Results: Fifty participants from each group completed all exams. Median age was 40 (25-49) vs. 36.5 (22-50) for the HIV and control groups, respectively (p 0.120). Ethnicity, body mass index, serum phosphorus, 25-hydroxyvitamin D, PTH and CTX were similar between groups, although ALP and OC suggested higher bone turnover in PLWH. VFA identified morphometric vertebral fractures in 12% of PLWH. PLWH had lower values for lumbar spine areal BMD and Z score, volumetric BMD, trabecular bone fraction (BV/TV) and trabecular number measured at the distal tibia by HR-pQCT; as a consequence, trabecular separation and heterogeneity were higher (all p < 0.05). The FRAX-estimated risk for hip and major osteoporotic fractures was statistically higher in PLWH (p < 0.001)., Conclusion: Our results confirm severe bone impairment and fractures associated with HIV in young patients. Thus, we developed a screening protocol for young PLWH to detect bone fragility, reduce skeletal disease progression and morbimortality, decrease fracture risk, and increase quality of life., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
9. Cushing's syndrome.
- Author
-
Gadelha M, Gatto F, Wildemberg LE, and Fleseriu M
- Subjects
- Humans, Quality of Life, Glucocorticoids therapeutic use, Cushing Syndrome diagnosis, Cushing Syndrome therapy
- Abstract
Endogenous Cushing's syndrome results from excess glucocorticoid secretion, which leads to a myriad of clinical manifestations, comorbidities, and increased mortality despite treatment. Molecular mechanisms and genetic alterations associated with different causes of Cushing's syndrome have been described in the last decade. Imaging modalities and biochemical testing have evolved; however, both the diagnosis and management of Cushing's syndrome remain challenging. Surgery is the preferred treatment for all causes, but medical therapy has markedly advanced, with new drug options becoming available. Nevertheless, several comorbidities remain even after patient remission, which can affect quality of life. Accurate and timely diagnosis and treatment are essential for mitigating chronic complications of excess glucocorticoids and improving patient quality of life. In this Seminar, we aim to update several important aspects of diagnosis, complications, and treatment of endogenous Cushing's syndrome of all causes., Competing Interests: Declaration of interests MG has received funding as principal investigator from Crinetics and Recordati in the last 3 years, has received personal honoraria for lectures, consulting, and advisory boards from Crinetics and Recordati, and is an Associate Editor of The Journal of Clinical Endocrinology and Metabolism. FG is an Associate Editor of Frontiers in Endocrinology (Translational Endocrinology), serves on the Executive Committee of the European Neuroendocrine Association, and has received personal honoraria for lectures, manuscript writing, and educational events from Ipsen, Novartis, Pfizer, and Recordati. LEW has received personal honoraria for lectures from Ipsen and is on the advisory board for Crinetics. MF has received funding from Crinetics, Recordati, Sparrow, and Xeris (previously Strongbridge) in the last 3 years as a principal investigator at the Oregon Health & Science University, has received personal honoraria for consulting and acting on advisory boards from Crinetics, HRA Pharma, Recordati, Sparrow, and Xeris (previously Strongbridge), is Deputy Editor of the European Journal of Endocrinology, and serves on the board of the Pituitary Society., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
10. Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience.
- Author
-
Gadelha M, Marques NV, Fialho C, Scaf C, Lamback E, Antunes X, Santos E, Magalhães J, and Wildemberg LE
- Subjects
- Humans, Insulin-Like Growth Factor I metabolism, Glycated Hemoglobin, Retrospective Studies, Quality of Life, Treatment Outcome, Growth Hormone therapeutic use, Glucose, Acromegaly drug therapy, Acromegaly etiology, Human Growth Hormone therapeutic use, Adenoma complications, Adenoma drug therapy
- Abstract
Context: Acromegaly is a rare, chronic, debilitating disorder caused by prolonged hypersecretion of growth hormone (GH) and overproduction of insulin-like growth factor I (IGF-I). Medical therapies, including the somatostatin receptor ligand (SRL) pasireotide, are frequently used to restore biochemical control., Objective: As patients often receive therapy over prolonged periods, long-term data from real-life settings are needed., Methods: A retrospective analysis was performed using a prospectively maintained database of all patients with acromegaly from our primary care center who were enrolled in clinical studies with pasireotide (first visit November 2008). The main outcome measures were safety and biochemical control (age-adjusted IGF-I ≤ upper limit of normal)., Results: Patients (n = 50) entered 4 parental studies and 30 continued in the rollover; at data cutoff (June 2022), 27 were still receiving pasireotide. Overall, median (range) exposure was 58 (3-137) months. Normal IGF-I was achieved in 54%, and acromegaly symptoms and quality of life were improved with treatment. No predictors of pasireotide response were identified; however, controlled patients had smaller tumors and lower GH at baseline. Tumor volume reduction occurred in 63% of evaluable patients (n = 10/16). Most patients presented hyperglycemic events, including 63.2% of patients with normal glucose before treatment. Older patients and those with higher IGF-I, glucose, and HbA1c at baseline had higher glucose and HbA1c during pasireotide treatment., Conclusion: Pasireotide provided clinical benefit and was well tolerated for more than 11 years of treatment in acromegaly patients, most of whom were resistant to first-generation SRLs., (© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society.)
- Published
- 2023
- Full Text
- View/download PDF
11. miR-383-5p, miR-181a-5p, and miR-181b-5p as Predictors of Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.
- Author
-
Henriques DG, Miranda RL, Dezonne RS, Wildemberg LE, Camacho AHDS, Chimelli L, Kasuki L, Lamback EB, Guterres A, and Gadelha MR
- Subjects
- Humans, Receptors, Somatostatin genetics, Acromegaly genetics, MicroRNAs genetics, MicroRNAs therapeutic use
- Abstract
Acromegaly is a chronic systemic disease caused in the vast majority of cases by growth hormone (GH)-secreting adenoma, with surgery being the first-line treatment. When a cure is not attained with surgery, first-generation somatostatin receptor ligands (fg-SRLs) are the most common medication prescribed. Predictors of response to fg-SRLs have been studied; however, they cannot fully predict the response to fg-SRL. MicroRNAs are small RNAs, the main role of which is messenger RNA (mRNA) post-transcriptional regulation. This study aimed to identify the microRNAs involved in resistance to treatment with fg-SRLs in acromegaly. Ten patients with acromegaly undergoing treatment with fg-SRLs were selected to undergo miRNA sequencing: five controlled and five uncontrolled with treatment. Bioinformatic analysis was performed to detect differentially expressed miRNAs. Then, the same 10 samples were used for validation by qPCR and an additional 22 samples were analyzed, totaling 32 samples. e We found 59 differentially expressed miRNAs in the first analysis. miR-181a-5p and miR-181b-5p were downregulated, and miR-383-5p was upregulated in the uncontrolled group. Receiver operating characteristic (ROC) curve analysis of miR-383-5p showed an NPV of 84.3% and a PPV of 84.5%. In summary, miR-181a-5p, miR-181b-5p, and miR-383-5p are biomarkers of response to fg-SRLs, and they can be used individually or included in prediction models as tools to guide clinical decisions.
- Published
- 2023
- Full Text
- View/download PDF
12. Routine Evaluation of Somatostatin Receptor Type 2 in Patients With Acromegaly: Do We Still Need More Evidence?
- Author
-
Gatto F, Wildemberg LE, Ferone D, and Gadelha MR
- Subjects
- Humans, Receptors, Somatostatin, Prospective Studies, Ligands, Octreotide, Acromegaly
- Abstract
Competing Interests: Conflict of Interest: F.G. received fees for lectures and/or participation to advisory boards for Novartis, AMCo, and IONIS Pharmaceuticals. L.E.W. received fees for lectures and/or participation to advisory board for Novartis and Crinetics; D.F. received fee for lectures, advisory boards, and steering committees participation for Novartis-AAA, Recordati, Camurus, and Sandoz. M.R.G. received fees for lectures and/or participation to advisory board for Novartis, Ipsen, Chiasma, and Crinetics.
- Published
- 2022
- Full Text
- View/download PDF
13. Pituitary acting drugs: cabergoline and pasireotide.
- Author
-
Gadelha MR, Wildemberg LE, and Shimon I
- Subjects
- Humans, Pituitary Gland pathology, Cabergoline therapeutic use, Pituitary ACTH Hypersecretion drug therapy, Pituitary ACTH Hypersecretion pathology, Somatostatin therapeutic use
- Abstract
First-line treatment for Cushing´s disease is transsphenoidal surgery. But in cases of persistent or recurrent disease after surgery, contraindications to surgery, severe hypercortisolism control before surgery, or for patients waiting for radiotherapy effects, medical therapy may be indicated. Pituitary-directed agents include cabergoline and pasireotide. Both drugs present similar potential for biochemical control and pasireotide has additionally been proved to reduce tumor volume. Moreover, pasireotide was evaluated in high quality studies. In respect to safety, both drugs are well tolerated and safe, but special attention should be given for cardiac valve disease and psychiatric disorder for cabergoline, and hyperglycemia for pasireotide., (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
14. Telomere length and Wnt/β-catenin pathway in adamantinomatous craniopharyngiomas.
- Author
-
Mota JIS, Silva-Júnior RMP, Martins CS, Bueno AC, Wildemberg LE, Antunes XLDS, Ozaki JGO, Coeli-Lacchini FB, Garcia-Peral C, Oliveira AER, Santos AC, Moreira AC, Machado HR, Dos Santos MV, Colli LM, Gadelha MR, Antonini SRR, and de Castro M
- Subjects
- Adolescent, Child, Cross-Sectional Studies, Humans, Mutation, Retrospective Studies, Wnt Signaling Pathway, Craniopharyngioma genetics, Telomere ultrastructure, beta Catenin genetics
- Abstract
Objectives: To evaluate how telomere length behaves in adamantinomtous craniopharyngioma (aCP) and if it contributes to the pathogenesis of aCPs with and without CTNNB1 mutations., Design: Retrospective cross-sectional study enrolling 42 aCP patients from 2 tertiary institutions., Methods: Clinicopathological features were retrieved from the patient's charts. Fresh frozen tumors were used for RNA and DNA analyses. Telomere length was evaluated by qPCR (T/S ratio). Somatic mutations in TERT promoter (TERTp) and CTNNB1 were detected by Sanger and/or whole-exome sequencing. We performed RNA-Seq to identify differentially expressed genes in aCPs presenting with shorter or longer telomere lengths., Results: Mutations in CTNNB1 were detected in 29 (69%) tumors. There was higher frequency of CTNNB1 mutations in aCPs from patients diagnosed under the age of 15 years (85% vs 15%; P = 0.04) and a trend to recurrent disease (76% vs 24%; P = 0.1). No mutation was detected in the TERTp region. The telomeres were shorter in CTNNB1-mutated aCPs (0.441, IQR: 0.297-0.597vs 0.607, IQR: 0.445-0.778; P = 0.04), but it was neither associated with clinicopathological features nor with recurrence. RNAseq identified a total of 387 differentially expressed genes, generating two clusters, being one enriched for short telomeres and CTNNB1-mutated aCPs., Conclusions: Ctnnb1: mutations are more frequent in children and adolescents and appear to associate with progressive disease. CTNNB1-mutated aCPs have shorter telomeres, demonstrating a relationship between the Wnt/β-catenin pathway and telomere biology in the pathogenesis of aCPs.
- Published
- 2022
- Full Text
- View/download PDF
15. Approach to the Patient: Differential Diagnosis of Cystic Sellar Lesions.
- Author
-
Gadelha MR, Wildemberg LE, Lamback EB, Barbosa MA, Kasuki L, and Ventura N
- Subjects
- Diagnosis, Differential, Humans, Magnetic Resonance Imaging methods, Adenoma diagnosis, Adenoma pathology, Central Nervous System Cysts diagnosis, Craniopharyngioma diagnosis, Craniopharyngioma pathology, Pituitary Neoplasms diagnosis, Pituitary Neoplasms pathology
- Abstract
Cystic lesions arising in the sellar region are not uncommon and encompass cystic pituitary adenomas, Rathke cleft cysts, craniopharyngiomas, and arachnoid cysts. Their clinical presentation may be similar, including headache, visual field defects, and anterior pituitary hormone deficits, which makes differential diagnosis challenging. On the other hand, imaging features may indicate certain pathologies. In this approach to the patient, we describe the case of a patient who presented with right temporal hemianopsia and a sellar/suprasellar cystic lesion, which was determined to be Rathke cleft cyst. We discuss the imaging characteristics that may suggest a particular diagnosis between Rathke cleft cyst, cystic pituitary adenoma, craniopharyngioma, and arachnoid cyst and propose a flowchart for aiding in the imaging differential diagnosis., (© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
16. Pituitary MRI Standard and Advanced Sequences: Role in the Diagnosis and Characterization of Pituitary Adenomas.
- Author
-
Gadelha MR, Barbosa MA, Lamback EB, Wildemberg LE, Kasuki L, and Ventura N
- Subjects
- Humans, Magnetic Resonance Imaging methods, Sella Turcica pathology, Adenoma diagnostic imaging, Adenoma pathology, Meningeal Neoplasms, Pituitary Diseases pathology, Pituitary Neoplasms diagnostic imaging, Pituitary Neoplasms pathology
- Abstract
Pituitary adenomas (PAs) represent the most frequently found lesions in the sellar region; however, several other lesions may be encountered in this region, such as meningiomas, craniopharyngiomas, and aneurysms. High-quality imaging is fundamental for diagnosis, characterization, and guidance of treatment planning of PAs. Sellar magnetic resonance imaging (MRI) is considered the imaging modality of choice for the evaluation of lesions in the sella turcica. The sellar MRI standard protocol includes coronal and sagittal T1-weighted spin-echo sequencing with and without gadolinium-based contrast agent and coronal T2-weighted (T2w) fast-spin echo sequencing. A systematic MRI approach to the pituitary region generally provides information that includes the size and shape of the PA, the presence of cysts or hemorrhage within the tumor, its relationship with the optic pathways and surrounding structures, potential cavernous sinus invasion, sphenoid sinus pneumatization type, and differential diagnosis with other sellar lesions. The standard protocol is sufficient for the evaluation of most cases; however, some advanced techniques (susceptibility imaging, diffusion-weighted imaging, 3D T2w high-resolution sequences, magnetic resonance elastography, perfusion-weighted imaging) may render additional information, which may be important for some cases. In this "approach to the patient" manuscript, we will discuss the use of standard and advanced MRI sequences in the diagnosis and characterization of PAs, including MRI features associated with treatment response that may aid in presurgical evaluation and planning, and red flags that may point to an alternative diagnosis., (© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
17. The Future of Somatostatin Receptor Ligands in Acromegaly.
- Author
-
Gadelha MR, Wildemberg LE, and Kasuki L
- Subjects
- Acromegaly blood, Acromegaly etiology, Antineoplastic Agents, Hormonal adverse effects, Biomarkers, Tumor blood, Growth Hormone-Secreting Pituitary Adenoma blood, Growth Hormone-Secreting Pituitary Adenoma complications, Growth Hormone-Secreting Pituitary Adenoma genetics, Humans, Octreotide administration & dosage, Octreotide adverse effects, Peptides, Cyclic administration & dosage, Peptides, Cyclic adverse effects, Precision Medicine methods, Precision Medicine trends, Quality of Life, Randomized Controlled Trials as Topic, Somatostatin administration & dosage, Somatostatin adverse effects, Somatostatin analogs & derivatives, Treatment Outcome, Acromegaly drug therapy, Antineoplastic Agents, Hormonal administration & dosage, Growth Hormone-Secreting Pituitary Adenoma drug therapy, Receptors, Somatostatin metabolism
- Abstract
Currently, the first-generation somatostatin receptor ligands (fg-SRLs), octreotide LAR and lanreotide autogel, are the mainstays of acromegaly treatment and achieve biochemical control in approximately 40% of patients and tumor shrinkage in over 60% of patients. Pasireotide, a second-generation SRL, shows higher efficacy with respect to both biochemical control and tumor shrinkage but has a worse safety profile. In this review, we discuss the future perspectives of currently available SRLs, focusing on the use of biomarkers of response and precision medicine, new formulations of these SRLs and new drugs, which are under development. Precision medicine, which is based on biomarkers of response to treatment, will help guide the decision-making process by allowing physicians to choose the appropriate drug for each patient and improving response rates. New formulations of available SRLs, such as oral, subcutaneous depot, and nasal octreotide, may improve patients' adherence to treatment and quality of life since there will be more options available that better suit each patient. Finally, new drugs, such as paltusotine, somatropin, ONO-5788, and ONO-ST-468, may improve treatment adherence and present higher efficacy than currently available drugs., (© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.)
- Published
- 2022
- Full Text
- View/download PDF
18. Prolactinomas.
- Author
-
Wildemberg LE, Fialho C, and Gadelha MR
- Subjects
- Antineoplastic Agents, Alkylating therapeutic use, Disruptive, Impulse Control, and Conduct Disorders diagnosis, Disruptive, Impulse Control, and Conduct Disorders etiology, Dopamine Agonists therapeutic use, Female, Galactorrhea etiology, Humans, Hyperprolactinemia etiology, Hypogonadism etiology, Pregnancy, Prolactin blood, Sella Turcica diagnostic imaging, Temozolomide therapeutic use, Pituitary Neoplasms complications, Pituitary Neoplasms diagnosis, Pituitary Neoplasms epidemiology, Pituitary Neoplasms therapy, Prolactinoma complications, Prolactinoma diagnosis, Prolactinoma epidemiology, Prolactinoma therapy
- Abstract
Hyperprolactinemia, defined by a level of serum prolactin above the standard upper limit of normal range, is a common finding in clinical practice and prolactinomas are the main pathological cause. Prolactinomas lead to signs and symptoms of hormone oversecretion, such as galactorrhea and hypogonadism, as well as symptoms of mass effect, including visual impairment, headaches and intracranial hypertension. Diagnosis involves prolactin measurement and sellar imaging, but several pitfalls are involved in this evaluation, which may difficult the proper management. Treatment is medical in the majority of cases, consisting of dopamine agonists, which present high response rates, with a very favorable safety profile. Major adverse effects that should be monitored consist of cardiac valvulopathy and impulse control disorders. Other treatment options include surgery and radiotherapy. Temozolomide may be used for aggressive or malignant carcinomas. Finally, pregnancy outcomes are similar to general population even when dopamine agonist treatment is maintained., (Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
19. Current opinion on the diagnosis and management of non-functioning pituitary adenomas.
- Author
-
Lamback EB, Wildemberg LE, and Gadelha MR
- Subjects
- Humans, Treatment Outcome, Adenoma diagnosis, Adenoma therapy, Pituitary Neoplasms diagnosis, Pituitary Neoplasms therapy
- Abstract
Introduction: Non-functioning pituitary adenomas (NFPAs) are clinically silent tumors and the second most common pituitary adenoma. Surgery is the mainstay of treatment as there is, as yet, no effective medical treatment., Areas Covered: We present current knowledge on the clinical diagnosis, histopathological classification, molecular data, and management strategies in NFPA., Expert Opinion: NFPA is a heterogeneous group of tumors, in respect to their origin and clinical course. In recent years, research on pathology and molecular biology have advanced our knowledge of NFPA pathogenesis. NFPA exhibit, in the majority of cases, an indolent behavior, with satisfactory response to treatment. In aggressive cases, multimodal management is needed; however, even this approach may be insufficient, so the development of new treatments is warranted for better management. In this setting, the understanding of the mechanisms involved in the genesis and progression of NFPA is crucial for the identification and development of directed treatments with higher chances of response.
- Published
- 2021
- Full Text
- View/download PDF
20. gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.
- Author
-
Wildemberg LE, Henriques D, Elias PCL, Lima CHA, Musolino NRC, Camacho AHS, Faria O, Nazato D, Abucham J, Vilar L, Mota JI, Huayllas MKP, Chimelli L, Castro M, Kasuki L, and Gadelha MR
- Abstract
Background: It is still controversial if activating mutations in the stimulatory G-protein α subunit ( gsp mutation) are a biomarker of response to first generation somatostatin receptor ligands (fg-SRL) treatment in acromegaly. Thus, we aimed to evaluate whether gsp mutation predicts long-term response to fg-SRL treatment and to characterize the phenotype of patients harboring gsp mutations., Methods: GNAS1 sequencing was performed by Sanger. SST2 and SST5 were analyzed by immunohistochemistry (IHC) and real-time RT-PCR. The cytokeratin granulation pattern was evaluated by IHC. Biochemical control was defined as GH < 1.0 ng/mL and normal age-adjusted IGF-I levels., Results: gsp mutation was found in 54 out of 136 patients evaluated. Biochemical control with fg-SRL treatment was similar in gsp + and gsp - patients (37% vs. 25%, p = 0.219). Tumors harboring gsp mutation were smaller ( p = 0.035) and had a lower chance of invading cavernous sinuses ( p = 0.001). SST5 protein ( p = 0.047) and mRNA ( p = 0.013) expression levels were higher in wild-type tumors., Conclusions: In this largest series available in the literature, we concluded that gsp is not a molecular biomarker of response to fg-SRL treatment in acromegaly. However, the importance of its negative association with cavernous sinus invasion and SST5 expression needs to be further investigated.
- Published
- 2021
- Full Text
- View/download PDF
21. Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands.
- Author
-
Wildemberg LE, da Silva Camacho AH, Miranda RL, Elias PCL, de Castro Musolino NR, Nazato D, Jallad R, Huayllas MKP, Mota JIS, Almeida T, Portes E, Ribeiro-Oliveira A, Vilar L, Boguszewski CL, Winter Tavares AB, Nunes-Nogueira VS, Mazzuco TL, Rech CGSL, Marques NV, Chimelli L, Czepielewski M, Bronstein MD, Abucham J, de Castro M, Kasuki L, and Gadelha M
- Subjects
- Acromegaly blood, Adult, Aged, Biomarkers blood, Female, Human Growth Hormone blood, Humans, Insulin-Like Growth Factor I metabolism, Keratins, Ligands, Logistic Models, Male, Middle Aged, Predictive Value of Tests, Receptors, Somatostatin blood, Treatment Outcome, Young Adult, Acromegaly drug therapy, Clinical Decision Rules, Drug Monitoring methods, Machine Learning, Receptors, Somatostatin administration & dosage
- Abstract
Context: Artificial intelligence (AI), in particular machine learning (ML), may be used to deeply analyze biomarkers of response to first-generation somatostatin receptor ligands (fg-SRLs) in the treatment of acromegaly., Objective: To develop a prediction model of therapeutic response of acromegaly to fg-SRL., Methods: Patients with acromegaly not cured by primary surgical treatment and who had adjuvant therapy with fg-SRL for at least 6 months after surgery were included. Patients were considered controlled if they presented growth hormone (GH) <1.0 ng/mL and normal age-adjusted insulin-like growth factor (IGF)-I levels. Six AI models were evaluated: logistic regression, k-nearest neighbor classifier, support vector machine, gradient-boosted classifier, random forest, and multilayer perceptron. The features included in the analysis were age at diagnosis, sex, GH, and IGF-I levels at diagnosis and at pretreatment, somatostatin receptor subtype 2 and 5 (SST2 and SST5) protein expression and cytokeratin granulation pattern (GP)., Results: A total of 153 patients were analyzed. Controlled patients were older (P = .002), had lower GH at diagnosis (P = .01), had lower pretreatment GH and IGF-I (P < .001), and more frequently harbored tumors that were densely granulated (P = .014) or highly expressed SST2 (P < .001). The model that performed best was the support vector machine with the features SST2, SST5, GP, sex, age, and pretreatment GH and IGF-I levels. It had an accuracy of 86.3%, positive predictive value of 83.3% and negative predictive value of 87.5%., Conclusion: We developed a ML-based prediction model with high accuracy that has the potential to improve medical management of acromegaly, optimize biochemical control, decrease long-term morbidities and mortality, and reduce health services costs., (© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
22. Splicing Machinery is Dysregulated in Pituitary Neuroendocrine Tumors and is Associated with Aggressiveness Features.
- Author
-
Vázquez-Borrego MC, Fuentes-Fayos AC, Venegas-Moreno E, Rivero-Cortés E, Dios E, Moreno-Moreno P, Madrazo-Atutxa A, Remón P, Solivera J, Wildemberg LE, Kasuki L, López-Fernández JM, Gadelha MR, Gálvez-Moreno MA, Soto-Moreno A, Gahete MD, Castaño JP, and Luque RM
- Abstract
Pituitary neuroendocrine tumors (PitNETs) constitute approximately 15% of all brain tumors, and most have a sporadic origin. Recent studies suggest that altered alternative splicing and, consequently, appearance of aberrant splicing variants, is a common feature of most tumor pathologies. Moreover, spliceosome is considered an attractive therapeutic target in tumor pathologies, and the inhibition of SF3B1 (e.g., using pladienolide-B) has been shown to exert antitumor effects. Therefore, we aimed to analyze the expression levels of selected splicing-machinery components in 261 PitNETs (somatotropinomas/non-functioning PitNETS/corticotropinomas/prolactinomas) and evaluated the direct effects of pladienolide-B in cell proliferation/viability/hormone secretion in human PitNETs cell cultures and pituitary cell lines (AtT-20/GH3). Results revealed a severe dysregulation of splicing-machinery components in all the PitNET subtypes compared to normal pituitaries and a unique fingerprint of splicing-machinery components that accurately discriminate between normal and tumor tissue in each PitNET subtype. Moreover, expression of specific components was associated with key clinical parameters. Interestingly, certain components were commonly dysregulated throughout all PitNET subtypes. Finally, pladienolide-B reduced cell proliferation/viability/hormone secretion in PitNET cell cultures and cell lines. Altogether, our data demonstrate a drastic dysregulation of the splicing-machinery in PitNETs that might be associated to their tumorigenesis, paving the way to explore the use of specific splicing-machinery components as novel diagnostic/prognostic and therapeutic targets in PitNETs., Competing Interests: The authors declare no conflict of interest.
- Published
- 2019
- Full Text
- View/download PDF
23. Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles.
- Author
-
Coelho MCA, Vasquez ML, Wildemberg LE, Vázquez-Borrego MC, Bitana L, Camacho AHDS, Silva D, Ogino LL, Ventura N, Sánchez-Sánchez R, Chimelli L, Kasuki L, Luque RM, and Gadelha MR
- Subjects
- Acromegaly etiology, Acromegaly metabolism, Adenoma complications, Adenoma genetics, Adenoma metabolism, Adolescent, Adult, Aged, Antineoplastic Agents therapeutic use, Cell Membrane genetics, Cell Membrane metabolism, Cell Nucleus genetics, Cell Nucleus metabolism, Cytoplasm genetics, Cytoplasm metabolism, Female, Filamins metabolism, Growth Hormone-Secreting Pituitary Adenoma complications, Growth Hormone-Secreting Pituitary Adenoma genetics, Growth Hormone-Secreting Pituitary Adenoma metabolism, Humans, Male, Middle Aged, Octreotide administration & dosage, Octreotide therapeutic use, Peptides, Cyclic administration & dosage, Peptides, Cyclic therapeutic use, Receptors, Dopamine D2 metabolism, Receptors, Somatostatin metabolism, Somatostatin administration & dosage, Somatostatin analogs & derivatives, Somatostatin therapeutic use, Tumor Burden, Young Adult, Acromegaly genetics, Adenoma drug therapy, Antineoplastic Agents administration & dosage, Filamins genetics, Growth Hormone-Secreting Pituitary Adenoma drug therapy, Receptors, Dopamine D2 genetics, Receptors, Somatostatin genetics
- Abstract
Filamin-A (FLNA) plays a crucial role in somatostatin receptor (sst) subtype-2 signaling in somatotropinomas. Our objective was to investigate the in vivo association between FLNA and sst2 expression, sst5 expression, dopamine receptor subtype-2 (D2) expression, somatostatin receptor ligand (SRL) responsiveness and tumor invasiveness in somatotropinomas. Quantitative real-time PCR was used to evaluate the absolute mRNA copy numbers of FLNA/sst2/sst5/D2 in 96 somatotropinomas. FLNA, sst2 and sst5 protein expression levels were also evaluated using immunohistochemistry. The Knosp-Steiner criteria were used to evaluate tumor invasiveness. Median FLNA, sst2, sst5 and D2 copy numbers were 4,244, 731, 156 and 3,989, respectively. Thirty-one of the 35 available tumors (89%) were immune positive for FLNA in the cytoplasm and membrane but not in the nucleus. FLNA and sst5 expression were positively correlated at the mRNA and protein levels (p < 0.001 and p = 0.033, respectively). FLNA was positively correlated with sst2 mRNA in patients who were responsive to SRL (p = 0.014, R = 0.659). No association was found between FLNA and tumor invasiveness. Our findings show that in somatotropinomas FLNA expression positively correlated with in vivo sst5 and D2 expression. Notably, FLNA was only correlated with sst2 in patients who were controlled with SRL. FLNA was not associated with tumor invasiveness.
- Published
- 2019
- Full Text
- View/download PDF
24. Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands.
- Author
-
Kasuki L, Dalmolin MD, Wildemberg LE, and Gadelha MR
- Subjects
- Adult, Aged, Female, Humans, Hyperprolactinemia drug therapy, Hyperprolactinemia metabolism, Male, Middle Aged, Receptors, Somatostatin agonists, Retrospective Studies, Young Adult, Acromegaly drug therapy, Acromegaly metabolism, Cabergoline therapeutic use, Receptors, Somatostatin metabolism
- Abstract
Background: Few studies evaluated the use of cabergoline (CAB) for acromegaly treatment in monotherapy or in combination with first-generation somatostatin receptor ligands (SRLs)., Aim: To evaluate the efficacy, predictors of response and safety of CAB treatment in acromegaly both in monotherapy and in combination with SRLs., Methods: We retrospectively collected demographic, biochemical, tumour and treatment data. Short-term disease control was defined as random GH level < 1.0 μg/L and normal age-matched IGF-I level after 3-6 months of treatment with the higher dose used. Long-term disease control was defined as maintenance of normal GH and IGF-I levels at the last visit (at least 9 months of treatment)., Results: Eighty-two patients were studied. The median total time of treatment in monotherapy or in combination with SRLs was 14 months (3-124) and 34 months (3-88), respectively. Short-term disease control was observed in 6 (21%) patients in the monotherapy group and in 20 (32%) in the combination group. Treatment escape was observed in 1 patient after 16 months of CAB monotherapy and in 6 (30%) patients with combination therapy (after a median of 38 months), resulting in long-term disease control of 18% and 23%, respectively. Hyperprolactinemia was a predictor of response to monotherapy and pretreatment GH level to combination treatment., Conclusion: We presented the results of the largest single-centre study with CAB in monotherapy and in combination with SRL. The efficacy of CAB in acromegaly seems to be lower than that of other drugs, and treatment escape may occur after a long-term follow-up., (© 2018 John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
25. Predictors of surgical outcome and early criteria of remission in acromegaly.
- Author
-
Antunes X, Ventura N, Camilo GB, Wildemberg LE, Guasti A, Pereira PJM, Camacho AHS, Chimelli L, Niemeyer P, Gadelha MR, and Kasuki L
- Subjects
- Acromegaly blood, Adenoma blood, Adult, Female, Humans, Male, Middle Aged, Pituitary Neoplasms blood, Postoperative Period, Prognosis, Remission Induction, Treatment Outcome, Acromegaly surgery, Adenoma surgery, Human Growth Hormone blood, Insulin-Like Growth Factor I metabolism, Pituitary Neoplasms surgery
- Abstract
Background: Transsphenoidal surgery (TSS) is the cornerstone of acromegaly treatment, however there are no robust predictors of surgical outcome and remission can only be defined three months after surgery., Purpose: To analyze if biochemical, demographical, radiological, and immunohistochemical characteristics are predictors of surgical remission and investigate if immediate postoperative GH and IGF-I levels can help defining remission earlier., Methods: Consecutive acromegaly patients submitted to TSS between 2013-2016 were evaluated. Remission criteria was defined as normal IGF-I and GH <1 mcg/L three months after surgery. Data of age, sex, GH and IGF-I levels, tumor volume, cavernous sinus invasion, T2-weighted signal, Ki-67, and granulation pattern were correlated with remission status. GH and IGF-I levels at 24, 48 h, and one week postoperative were evaluated as early criteria of remission., Results: Sixty-nine patients were included (84% macroadenomas) and surgical remission was achieved in 45%. No difference between cured and not cured patients concerning age, gender, preoperative GH or IGF-I levels, tumor volume, T2-weighted signal, Ki-67 and tumor granularity was observed. Remission was obtained in 20 of 36 (56%) of the non-invasive tumors, and in 3 of 16 (19%) of the invasive tumors (p = 0.017). A GH <1.57 mcg/L 48 h after surgery was able to predict remission with 93% sensitivity and 86% specificity and an IGF-I < 231% ULNR one week after surgery predicted remission with 86% sensitivity and 93% specificity., Conclusion: Cavernous sinus invasion is the only preoperative predictor of surgical remission. GH at 48 h and IGF-I one week after surgery can define earlier not cured patients.
- Published
- 2018
- Full Text
- View/download PDF
26. Apoplexy in nonfunctioning pituitary adenomas.
- Author
-
Wildemberg LE, Glezer A, Bronstein MD, and Gadelha MR
- Subjects
- Animals, Humans, Pituitary Apoplexy pathology, Pituitary Diseases pathology, Neoplasm Recurrence, Local pathology, Pituitary Neoplasms pathology
- Abstract
Pituitary apoplexy is an uncommon event, occurring due to the infarction and/or haemorrhage usually of a previously unknown pituitary adenoma. It can occur in all adenoma subtypes but is more common in nonfunctioning pituitary adenomas. The physiopathology is not completely clear, and precipitating factors, such as major surgeries, anticoagulant use or pituitary dynamic tests, can be found in up to 40% of patients. The clinical presentation is characterized by a rapid onset with a headache as the main symptom, but visual disturbances can also be present as well as meningism and intracranial hypertension. The diagnosis is based on imaging evaluations, mainly using magnetic resonance imaging, which can show various patterns depending on the timeframe following the occurrence of the apoplectic event. Pituitary hormonal deficits are also common, and the evaluation of hormonal levels is mandatory. Pituitary apoplexy can be managed by surgery or conservative treatment, and a multidisciplinary team is essential for the decision-making process. The outcome is usually positive with both surgical and conservative approaches, but surveillance is needed due to the risk of re-bleeding or tumour recurrence.
- Published
- 2018
- Full Text
- View/download PDF
27. Molecular evidence and clinical importance of β-arrestins expression in patients with acromegaly.
- Author
-
Coelho MCA, Vasquez ML, Wildemberg LE, Vázquez-Borrego MC, Bitana L, Camacho AHDS, Silva D, Ogino LL, Ventura N, Chimelli L, Luque RM, Kasuki L, and Gadelha MR
- Subjects
- Adolescent, Adult, Aged, Female, Gene Expression Regulation, Humans, Ligands, Male, Middle Aged, Neoplasm Invasiveness, RNA, Messenger genetics, RNA, Messenger metabolism, Receptors, Somatostatin metabolism, Young Adult, beta-Arrestins metabolism, Acromegaly genetics, beta-Arrestins genetics
- Abstract
β-arrestins seem to have a role in endocytosis and desensitization of somatostatin receptor subtype 2 (sst2) and could be associated with the responsiveness to somatostatin receptor ligands (SRL) in patients with acromegaly. To investigate the in vivo correlation between β-arrestins 1 and 2 with sst2, sst5 and dopamine receptor subtype 2 (D2) expressions, and the association of β-arrestins with response to first-generation SRL and invasiveness in somatotropinomas. β-arrestins 1 and 2, sst2, sst5 and D2 mRNA expressions were evaluated by quantitative real-time RT-PCR on tumoral tissue of 96 patients. Moreover, sst2 and sst5 protein expressions were also evaluated in 40 somatotropinomas by immunohistochemistry. Response to SRL, defined as GH <1 μg/l and normal IGF-I levels, was assessed in 40 patients. The Knosp-Steiner criteria were used to define invasiveness. Median β-arrestin 1, β-arrestin 2, sst2, sst5 and D2 mRNA copy numbers were 478; 9375; 731; 156; and 3989, respectively. There was a positive correlation between β-arrestins 1 and 2 (R = 0.444, P < 0.001). However, no correlation between β-arrestins and sst2, sst5 (mRNA and protein levels) or D2 was found. No association was found between β-arrestins expression and SRL responsiveness or tumour invasiveness. Although previous data suggest a putative correlation between β-arrestins and sst2, our data clearly indicated that no association existed between β-arrestins and sst2, sst5 or D2 expression, nor with response to SRL or tumour invasiveness. Therefore, further studies are required to clarify whether β-arrestins have a role in the response to treatment with SRL in acromegaly., (© 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.)
- Published
- 2018
- Full Text
- View/download PDF
28. MANAGEMENT OF ENDOCRINE DISEASE: Personalized medicine in the treatment of acromegaly.
- Author
-
Kasuki L, Wildemberg LE, and Gadelha MR
- Subjects
- Humans, Treatment Outcome, Acromegaly drug therapy, Adenoma drug therapy, Dopamine Agonists therapeutic use, Growth Hormone-Secreting Pituitary Adenoma drug therapy, Precision Medicine, Receptors, Somatotropin antagonists & inhibitors, Somatostatin analogs & derivatives
- Abstract
Acromegaly is associated with high morbidity and elevated mortality when not adequately treated. Surgery is the first-line treatment for most patients as it is the only one that can lead to immediate cure. In patients who are not cured by surgery, treatment is currently based on a trial-and-error approach. First-generation somatostatin receptor ligands (fg-SRL) are initiated for most patients, although approximately 25% of patients present resistance to this drug class. Some biomarkers of treatment outcome are described in the literature, with the aim of categorizing patients into different groups to individualize their treatments using a personalized approach. In this review, we will discuss the current status of precision medicine for the treatment of acromegaly and future perspectives on the use of personalized medicine for this purpose., (© 2018 European Society of Endocrinology.)
- Published
- 2018
- Full Text
- View/download PDF
29. Frequency of familial pituitary adenoma syndromes among patients with functioning pituitary adenomas in a reference outpatient clinic.
- Author
-
Marques NV, Kasuki L, Coelho MC, Lima CHA, Wildemberg LE, and Gadelha MR
- Subjects
- Adult, Aged, Aged, 80 and over, Ambulatory Care Facilities, Cross-Sectional Studies, Female, Follow-Up Studies, Growth Hormone-Secreting Pituitary Adenoma genetics, Growth Hormone-Secreting Pituitary Adenoma pathology, Humans, Inheritance Patterns, Male, Middle Aged, Pituitary ACTH Hypersecretion genetics, Pituitary ACTH Hypersecretion pathology, Pituitary Neoplasms genetics, Pituitary Neoplasms pathology, Prognosis, Reference Standards, Syndrome, Young Adult, Genetic Predisposition to Disease, Growth Hormone-Secreting Pituitary Adenoma epidemiology, Intracellular Signaling Peptides and Proteins genetics, Mutation, Pituitary ACTH Hypersecretion epidemiology, Pituitary Neoplasms epidemiology
- Abstract
Introduction: Pituitary adenomas (PA) occur mainly as sporadic disease, but familial syndromes are found in approximately 5% of cases. Identification of these syndromes is important in order to diagnose individuals at risk at an earlier stage., Aims: To evaluate the frequency of familial PA in a reference outpatient clinic devoted to PA treatment and to identify family members suspected to have pituitary disease., Methods: Patients with PA were interviewed with respect to the presence of family members with diagnosis of PA or with signs or symptoms suggestive of them. The family members who had a clinical picture suggestive of pituitary disease were further evaluated in an attempt to identify new PA cases. In families with familial disease, the AIP gene was sequenced., Results: 262 patients were evaluated and familial syndrome was found in 13 (5%). Ten (3.8%) patients had familial isolated PA (FIPA) and three (1.2%) had multiple endocrine neoplasia type 1. After evaluation of family members' symptomatology, 110 were considered suspected of having pituitary disease, but only 24 participated in the study. Of these 24, 1 was diagnosed with a corticotropinoma. AIP mutations were found in 20% of FIPA families., Conclusion: We found a frequency of familial PA similar to that previously described, as well as a similar frequency of AIP mutations among FIPA families. An active search of the affected family members was able to identify one case of Cushing´s disease. Patients should be aware of pituitary disease's clinical picture to identify possibly affected family members.
- Published
- 2017
- Full Text
- View/download PDF
30. Somatostatin receptor ligands in the treatment of acromegaly.
- Author
-
Gadelha MR, Wildemberg LE, Bronstein MD, Gatto F, and Ferone D
- Subjects
- Acromegaly metabolism, Humans, Octreotide therapeutic use, Peptides, Cyclic therapeutic use, Receptors, Somatostatin agonists, Somatostatin analogs & derivatives, Somatostatin therapeutic use, Acromegaly drug therapy, Receptors, Somatostatin metabolism
- Abstract
First-generation somatostatin receptors ligands (SRL) are the mainstay in the medical treatment of acromegaly, however the percentage of patients controlled with these drugs significantly varies in the different studies. Many factors are involved in the resistance to SRL. In this review, we update the physiology of somatostatin and its receptors (sst), the use of SRL in the treatment of acromegaly and the factors involved in the response to these drugs. The SRL act through interaction with the sst, which up to now have been characterized as five subtypes. The first-generation SRL, octreotide and lanreotide, are considered sst2 specific and have biochemical response rates varying from 20 to 70%. Tumor volume reduction can be found in 36-75% of patients. Several factors may determine the response to these drugs, such as sst, AIP, E-cadherin, ZAC1, filamin A and β-arrestin expression in the somatotropinomas. In patients resistant to first-generation SRL, alternative medical treatment options include: SRL high dose regimens, SRL in combination with cabergoline or pegvisomant, or the use of pasireotide. Pasireotide is a next-generation SRL with a broader pattern of interaction with sst. In the light of the recent increase of treatment options in acromegaly and the deeper knowledge of the determinants of response to the current first-line therapy, a shift from a trial-and-error treatment to a personalized one could be possible.
- Published
- 2017
- Full Text
- View/download PDF
31. Somatotropinomas inadequately controlled with octreotide may over-respond to pasireotide: the importance of dose adjustment to achieve long-term biochemical control.
- Author
-
Shimon I, Saeger W, Wildemberg LE, and Gadelha MR
- Subjects
- Acromegaly drug therapy, Adenoma pathology, Adult, Antineoplastic Agents, Hormonal administration & dosage, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Growth Hormone-Secreting Pituitary Adenoma pathology, Hormones administration & dosage, Humans, Middle Aged, Octreotide administration & dosage, Somatostatin administration & dosage, Somatostatin therapeutic use, Adenoma drug therapy, Antineoplastic Agents, Hormonal therapeutic use, Growth Hormone-Secreting Pituitary Adenoma drug therapy, Hormones therapeutic use, Octreotide therapeutic use, Somatostatin analogs & derivatives
- Abstract
Objective: To present two female patients with acromegaly inadequately controlled with long-acting octreotide who were subsequently treated with the multireceptor-targeted somatostatin analogue pasireotide that over-suppressed IGF-1 levels., Methods: We report two patients who failed surgery and received long-acting octreotide 20-30 mg/month as part of two double-blind, Phase III clinical trials. After 6-12 months of octreotide treatment, both patients remained inadequately controlled and were switched to long-acting pasireotide 40 mg/month as part of a crossover extension phase., Results: During the core phase of the studies the patients received octreotide 20-30 mg/month, but GH and IGF-1 levels remained above normal. They were switched to pasireotide 40 mg/month after 6 and 12 months, according to the study protocols. After crossover, GH and IGF-1 decreased and normalized, but continued treatment led to further reduction of IGF-1 to below the normal; these reduced levels mildly increased following pasireotide dose reduction to 20 mg/month. Tumour volume was reduced and the clinical signs and symptoms of acromegaly also improved., Conclusion: These patients achieved long-term biochemical control, tumour volume reduction and improvement of clinical signs/symptoms after switching from octreotide to pasireotide. IGF-1 over-suppression is observed in a few patients and requires dose adjustment of pasireotide.
- Published
- 2017
- Full Text
- View/download PDF
32. Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response.
- Author
-
Kasuki L, Machado EO, Ogino LL, Coelho MC, Silva CM, Wildemberg LE, Lima CH, and Gadelha MR
- Abstract
Objective: To describe the safety and efficacy of pegvisomant therapy and the predictors of treatment response in acromegaly patients at a single tertiary reference center in Brazil., Materials and Methods: We retrospectively reviewed the clinical, hormonal and radiological data of acromegaly patients treated with pegvisomant in our center. We also evaluated the presence of the d3 isoform of the growth hormone receptor (d3GHR)., Results: Twenty-seven patients were included (17 women). Pegvisomant was used in combination with octreotide LAR in 20 patients (74%), in combination with cabergoline in one (4%) and as monotherapy in six (22%). IGF-I normalization was achieved in 23 patients (85%). Mild and transitory elevation of liver enzymes was observed in two patients (7.4%), tumor growth in one (3.4%) and lipodystrophy in two (7.4%). One patient stopped the drug due to headaches. The GHR isoforms were evaluated in 14 patients, and the presence of at least one d3GHR allele was observed in 43% of them, but it was not a predictor of treatment response. Only pre-treatment IGF-I level was a predictor of treatment response., Conclusion: Pegvisomant treatment was highly effective and safe in our series of Brazilian patients. A better chance of disease control can be expected in those with lower pre-pegvisomant IGF-I levels.
- Published
- 2016
- Full Text
- View/download PDF
33. Pasireotide for the treatment of acromegaly.
- Author
-
Wildemberg LE and Gadelha MR
- Subjects
- Acromegaly complications, Animals, Antineoplastic Agents therapeutic use, Clinical Trials as Topic, Colonic Neoplasms complications, Colonic Neoplasms drug therapy, Humans, Somatostatin pharmacokinetics, Somatostatin pharmacology, Somatostatin therapeutic use, Thyroid Neoplasms complications, Thyroid Neoplasms drug therapy, Acromegaly drug therapy, Somatostatin analogs & derivatives
- Abstract
Introduction: Acromegaly is a chronic disease with high morbidity and enhanced mortality if left untreated. Treatment options include surgery, medical therapy (somatostatin analogues (SA), dopamine agonists (DA) and growth hormone receptor antagonists) and radiotherapy. Despite these treatment options, "real-life" studies have shown that approximately 50% of patients are not controlled. In this scenario, a next-generation SA, pasireotide, has recently been approved for the treatment of acromegaly., Areas Covered: 1) pasireotide's pharmacokinetics and pharmacodynamics; 2) pasireotide's anti-secretory and anti-proliferative effects, from preclinical studies up to phase III clinical trials; and 3) the adverse effects of pasireotide, focusing on hyperglycemia; 4) biomarkers of response to SA treatment., Expert Opinion: surgery is the primary treatment for most patients with acromegaly; however, approximately half of them will need adjuvant therapy. At present, the decision of this adjuvant treatment is made on a "trial-and-error" fashion. Nevertheless, in recent years, efforts have been made to establish biomarkers for the response to drugs involved in the treatment of acromegaly, which will change the treatment of acromegaly towards a more personalized therapeutic decision-making process. In the near future, the establishment of pasireotide response biomarkers will allow us to identify good candidates for first-line medical monotherapy with pasireotide.
- Published
- 2016
- Full Text
- View/download PDF
34. The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease.
- Author
-
Perez-Rivas LG, Theodoropoulou M, Ferraù F, Nusser C, Kawaguchi K, Stratakis CA, Faucz FR, Wildemberg LE, Assié G, Beschorner R, Dimopoulou C, Buchfelder M, Popovic V, Berr CM, Tóth M, Ardisasmita AI, Honegger J, Bertherat J, Gadelha MR, Beuschlein F, Stalla G, Komada M, Korbonits M, and Reincke M
- Subjects
- ACTH-Secreting Pituitary Adenoma epidemiology, Adenoma epidemiology, Adolescent, Adult, Animals, COS Cells, Child, Chlorocebus aethiops, DNA Mutational Analysis, Female, Gene Frequency, Genetic Association Studies, HeLa Cells, Humans, Male, Mice, Middle Aged, Pituitary ACTH Hypersecretion epidemiology, Retrospective Studies, Tumor Cells, Cultured, Young Adult, ACTH-Secreting Pituitary Adenoma genetics, Adenoma genetics, Endopeptidases genetics, Endosomal Sorting Complexes Required for Transport genetics, Mutation, Pituitary ACTH Hypersecretion genetics, Ubiquitin Thiolesterase genetics
- Abstract
Context: We have recently reported somatic mutations in the ubiquitin-specific protease USP8 gene in a small series of adenomas of patients with Cushing's disease., Objective: To determine the prevalence of USP8 mutations and the genotype-phenotype correlation in a large series of patients diagnosed with Cushing's disease., Design: We performed a retrospective, multicentric, genetic analysis of 134 functioning and 11 silent corticotroph adenomas using Sanger sequencing. Biochemical and clinical features were collected and examined within the context of the mutational status of USP8, and new mutations were characterized by functional studies., Patients: A total of 145 patients who underwent surgery for an ACTH-producing pituitary adenoma., Main Outcomes Measures: Mutational status of USP8. Biochemical and clinical features included sex, age at diagnosis, tumor size, preoperative and postoperative hormonal levels, and comorbidities., Results: We found somatic mutations in USP8 in 48 (36%) pituitary adenomas from patients with Cushing's disease but in none of 11 silent corticotropinomas. The prevalence was higher in adults than in pediatric cases (41 vs 17%) and in females than in males (43 vs 17%). Adults having USP8-mutated adenomas were diagnosed at an earlier age than those with wild-type lesions (36 vs 44 y). Mutations were primarily found in adenomas of 10 ± 7 mm and were inversely associated with the development of postoperative adrenal insufficiency. All the mutations affected the residues Ser718 or Pro720, including five new identified alterations. Mutations reduced the interaction between USP8 and 14-3-3 and enhanced USP8 activity. USP8 mutants diminished epidermal growth factor receptor ubiquitination and induced Pomc promoter activity in immortalized AtT-20 corticotropinoma cells., Conclusions: USP8 is frequently mutated in adenomas causing Cushing's disease, especially in those from female adult patients diagnosed at a younger age.
- Published
- 2015
- Full Text
- View/download PDF
35. Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy.
- Author
-
Vieira Neto L, Wildemberg LE, Moraes AB, Colli LM, Kasuki L, Marques NV, Gasparetto EL, de Castro M, Takiya CM, and Gadelha MR
- Subjects
- Adult, Aged, Antineoplastic Agents therapeutic use, Cabergoline, Female, Gene Expression Regulation, Neoplastic, Humans, Ki-67 Antigen metabolism, Magnetic Resonance Imaging, Male, Middle Aged, Pituitary Gland metabolism, RNA, Messenger metabolism, Treatment Outcome, Adenoma drug therapy, Adenoma metabolism, Ergolines therapeutic use, Pituitary Neoplasms drug therapy, Pituitary Neoplasms metabolism, Receptors, Dopamine D2 metabolism
- Abstract
Objectives: To determine the dopamine receptor subtype 2 (DR2) mRNA levels and protein expression and to evaluate the effect of adjuvant cabergoline therapy on tumour volume (TV) in patients with postoperative residual nonfunctioning pituitary adenoma (NFPA)., Methods: The mRNA expression was quantified by real-time RT-PCR (TaqMan(®)), and protein expression was evaluated by immunohistochemistry. Tumours were classified according to the percentage of immunostained cells for DR2 as scores 1 (<50% of stained cells) or 2 (≥50%). Cabergoline was started at least 6 months after surgery in nine patients with residual tumours (3 mg/week). The cabergoline effect was prospectively evaluated by magnetic resonance imaging using three-dimensional volume calculation. TV reduction >25% was considered significant., Results: The DR2 mRNA expression was variable but was observed in 100% of the samples (N = 20). DR2 protein expression was also observed in all the tumours (N = 34). Twenty-nine tumours (85%) were classified as score 2. The median DR2 mRNA expression was higher in the tumours classified as score 2 compared with score 1 (P = 0·007). TV reduction with cabergoline therapy was observed in 67% of the patients (6/9). The median TV before and after 6 months of treatment was 1·90 cm(3) (0·61-8·74) and 1·69 cm(3) (0·36-4·20) [P = 0·02], respectively., Conclusion: In conclusion, DR2 is expressed in all adenomas and the majority of the patients in this study displayed tumour shrinkage on cabergoline (CAB) therapy. Thus, CAB might be useful in adjuvant therapy in NFPA patients with residual tumours after surgery., (© 2014 John Wiley & Sons Ltd.)
- Published
- 2015
- Full Text
- View/download PDF
36. Rotation thromboelastometry and the hypercoagulable state in Cushing's syndrome.
- Author
-
Coelho MC, Vieira Neto L, Kasuki L, Wildemberg LE, Santos CV, Castro G, Gouvêa G, Veloso OC, Gadelha T, and Gadelha MR
- Subjects
- Adult, Case-Control Studies, Female, Hemostasis, Humans, Male, Middle Aged, Rotation, Blood Coagulation, Cushing Syndrome blood, Cushing Syndrome complications, Thrombelastography methods, Thrombophilia blood, Thrombophilia complications
- Abstract
Introduction: Rotation thromboelastometry (ROTEM®) can be used for hypercoagulability evaluation. Cushing's syndrome (CS) is associated with hypercoagulability; however, ROTEM® has never been evaluated in this setting., Objective: To evaluate hypercoagulability in CS using ROTEM® and to correlate these parameters with coagulation markers and with the presence of deep vein thrombosis., Design and Methods: Thirty patients with active CS (26 women) and 30 controls matched for age, sex, body mass index, diabetes mellitus, arterial hypertension, ABO blood group and smoking were included. We measured levels of activated partial thromboplastin time (aPTT), platelets, fibrinogen, D-dimer, factor VIII (FVIII), von Willebrand factor (vWF) and C-reactive protein. ROTEM® was used to evaluate the intrinsic (INTEM), extrinsic (EXTEM) and fibrinogen (FIBTEM) pathways. Doppler ultrasonography was performed to search for lower limbs deep vein thrombosis., Results: INTEM clotting time using ROTEM® was shorter in patients than in controls (P = 0·04). Other ROTEM® parameters were not different. Mean aPTT was shorter in patients than in controls (P = 0·001). The FVIII, vWF and D-dimer levels were higher in patients than in controls (P = 0·001, 0·001 and 0·02, respectively). Obese CS patients presented higher levels of platelets and alterations in maximum clot formation (MCF), alpha angle and maximum speed of clot formation of INTEM (P = 0·03, 0·02 and 0·02, respectively) and an increase in the MCF of FIBTEM (P = 0·02). No deep vein thrombosis was found., Conclusions: Although FVIII and vWF were abnormal in CS patients, only the initiation clot formation was different in the ROTEM® methodology and no deep vein thrombosis was found., (© 2014 John Wiley & Sons Ltd.)
- Published
- 2014
- Full Text
- View/download PDF
37. The role of temozolomide in the treatment of a patient with a pure silent pituitary somatotroph carcinoma.
- Author
-
Vieira Neto L, Chimelli L, Pereira PJ, Gasparetto EL, Bines J, Wildemberg LE, and Gadelha MR
- Subjects
- Antineoplastic Agents, Hormonal therapeutic use, Bone Neoplasms secondary, Dacarbazine therapeutic use, Diphosphonates therapeutic use, Female, Growth Hormone-Secreting Pituitary Adenoma pathology, Human Growth Hormone blood, Humans, Imidazoles therapeutic use, Liver Neoplasms secondary, Magnetic Resonance Imaging, Middle Aged, Neoplasm Recurrence, Local drug therapy, Octreotide therapeutic use, Pituitary Neoplasms pathology, Temozolomide, Zoledronic Acid, Antineoplastic Agents, Alkylating therapeutic use, Dacarbazine analogs & derivatives, Growth Hormone-Secreting Pituitary Adenoma drug therapy, Pituitary Neoplasms drug therapy
- Abstract
Objective: To describe a case of a pure silent somatotroph pituitary carcinoma., Methods: We describe a 54-year-old female with a clinically nonfunctioning pituitary macroadenoma diagnosed 15 years earlier., Results: The patient underwent transsphenoidal surgery and no visible tumor remnant was observed for 6 years. A magnetic resonance imaging (MRI) detected the recurrence of a 1.2 × 1.5 cm macroadenoma. The patient was submitted to conventional radiotherapy (4500 cGy), and the tumor volume remained stable for 7 years. Then, an MRI revealed a slight increase in tumor size, and 2 years later, a subsequent MRI detected a very large, invasive pituitary mass. The patient was resubmitted to transsphenoidal surgery, and the histopathological examination showed diffuse positivity for growth hormone (GH). The nadir GH level during an oral glucose tolerance test was 0.06 ng/mL, and the pre- and postoperative insulin like growth factor type I (IGF-I) levels were within the normal range. Abdominal, chest, brain, and spine MRI showed multiple small and hypervascular liver and bone lesions suggestive of metastases. Liver biopsy confirmed metastasis of GH-producing pituitary carcinoma. The patient has been treated with temozolomide and zoledronic acid for 7 months and with octreotide long-acting release (LAR) for 4 months. The primary tumor and metastases are stable., Conclusion: Despite being an extremely rare event, pituitary carcinoma may develop several years after the successful treatment of even a silent GH-producing pituitary adenoma, which suggests that close long-term follow-up is necessary.
- Published
- 2013
- Full Text
- View/download PDF
38. ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas.
- Author
-
Vieria Neto L, Wildemberg LE, Colli LM, Kasuki L, Marques NV, Moraes AB, Gasparetto EL, Takiya CM, Castro M, and Gadelha MR
- Subjects
- Adenoma drug therapy, Adenoma metabolism, Adenoma pathology, Adult, Aged, Case-Control Studies, Cell Cycle Proteins metabolism, Female, Growth Hormone-Secreting Pituitary Adenoma drug therapy, Growth Hormone-Secreting Pituitary Adenoma metabolism, Growth Hormone-Secreting Pituitary Adenoma pathology, Humans, Ki-67 Antigen genetics, Ki-67 Antigen metabolism, Male, Middle Aged, Pituitary Gland drug effects, Pituitary Gland metabolism, Pituitary Gland pathology, Pituitary Neoplasms drug therapy, Pituitary Neoplasms metabolism, Pituitary Neoplasms pathology, Receptors, Somatostatin metabolism, Somatostatin analogs & derivatives, Somatostatin therapeutic use, Transcription Factors metabolism, Tumor Suppressor Protein p53 genetics, Tumor Suppressor Protein p53 metabolism, Tumor Suppressor Proteins metabolism, Adenoma genetics, Cell Cycle Proteins genetics, Gene Expression Regulation, Neoplastic, Growth Hormone-Secreting Pituitary Adenoma genetics, Pituitary Neoplasms genetics, Receptors, Somatostatin genetics, Transcription Factors genetics, Tumor Suppressor Proteins genetics
- Abstract
Introduction: There are few data regarding ZAC1 expression in clinically non-functioning pituitary adenomas (NFPA). Because somatotropinomas and NFPA behave differently with respect to tumor shrinkage during somatostatin analogs (SA) therapy, we sought to compare the ZAC1 and somatostatin receptor (sstr) types 1, 2, 3 and 5 mRNA expression in these two pituitary adenoma subtypes and in normal human pituitaries., Methods: ZAC1 and SSTR mRNA expression levels were evaluated using real-time RT-PCR (TaqMan) in 20 NFPA and compared with the expression levels in 23 somatotropinomas and five normal pituitaries. The NFPA invasiveness was evaluated using magnetic resonance imaging with Hardy's modified criteria. Ki-67 and p53 were evaluated using immunohistochemistry., Results: A total of 20 patients with NFPA [6 males, median age 56 years (range: 30-78)], 23 with acromegaly [12 males, median age 43 years (range: 24-57)] and five normal pituitaries [4 males, median age 48 years (range: 36-54)] were included. Four of the patients (20%) had Hardy's grade 2 tumors; all of the others had Hardy's grade 3 tumors. The Ki-67 median expression was 2.35 (range: 0.2-9.23), and only four of the tumors (20%) were positive for p53. The ZAC1 mRNA expression was significantly lower in NFPA than in somatotropinomas and in normal pituitaries (p<0.001 for both), as well as the SSTR2 (p=0.001 and 0.01, respectively). The SSTR3 expression was higher in the NFPA than in the somatotropinomas and in the normal pituitaries (p=0.03 and 0.02, respectively). No correlation was found between the ZAC1 mRNA expression and the tumor invasiveness, Ki-67 and p53., Conclusion: ZAC1 and SSTR2 are underexpressed and SSTR3 is overexpressed in NFPA compared to those in somatotropinomas and in normal pituitaries, which might explain the lack of tumor shrinkage that is observed in response to commercially available SA therapy in patients with NFPA.
- Published
- 2013
- Full Text
- View/download PDF
39. Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern.
- Author
-
Kasuki L, Wildemberg LE, Neto LV, Marcondes J, Takiya CM, and Gadelha MR
- Subjects
- Acromegaly drug therapy, Adult, Female, Humans, Immunohistochemistry, Logistic Models, Middle Aged, Multivariate Analysis, Receptors, Somatostatin metabolism, Young Adult, Acromegaly metabolism, Antineoplastic Agents, Hormonal therapeutic use, Keratins metabolism, Ki-67 Antigen metabolism, Octreotide therapeutic use, Pituitary Neoplasms metabolism
- Abstract
Introduction: Only one study has evaluated Ki-67 as a predictor of the response to somatostatin analog therapy in acromegaly; however, other predictors like somatostatin receptor type 2 (SSTR2) and cytokeratin pattern expressions were not considered., Objective: To evaluate whether Ki-67 is a predictor of octreotide LAR (OCT-LAR) response in somatotropinomas independent of SSTR2 and cytokeratin expression patterns., Methods: Protein expression was analyzed by immunohistochemistry. The percentage of cell nuclei that were immunolabeled for Ki-67 and the percentage of cells with positive SSTR2 staining were calculated. SSTR2 expression was considered high when ≥25%, and a cutoff of 2.3% was designated for Ki-67. Tumors were classified as densely or sparsely granulated according to the cytokeratin pattern., Results: Thirty-one somatotropinomas were studied. Fourteen patients (45.2%) were controlled with OCT-LAR therapy. The median Ki-67 labeling index (LI) was higher in patients not controlled with OCT-LAR than in those controlled (1.63 and 0.15 respectively, P=0.002). Higher SSTR2 expression and densely granulated tumors were correlated with control as well (P=0.04 and 0.038 respectively). There was no difference in Ki-67 levels between patients with high and low SSTR2 expression (P=0.651). After multivariate analysis, both Ki-67 and SSTR2 remained statistically significant as predictors of OCT-LAR response (P=0.017 and 0.012 respectively). The Ki-67 LI was higher in sparsely than in densely granulated tumors (P=0.047)., Conclusions: Ki-67 is a predictor of response to OCT-LAR in acromegaly, independent of SSTR2 expression and relates to cytokeratin patterns.
- Published
- 2013
- Full Text
- View/download PDF
40. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs.
- Author
-
Wildemberg LE, Neto LV, Costa DF, Nasciuti LE, Takiya CM, Alves LM, Rebora A, Minuto F, Ferone D, and Gadelha MR
- Subjects
- Acromegaly metabolism, Adult, Aged, Case-Control Studies, Female, Growth Hormone-Secreting Pituitary Adenoma metabolism, Human Growth Hormone metabolism, Humans, Immunoenzyme Techniques, Insulin-Like Growth Factor I metabolism, Male, Middle Aged, Prognosis, Young Adult, Acromegaly drug therapy, Antineoplastic Agents, Hormonal therapeutic use, Growth Hormone-Secreting Pituitary Adenoma drug therapy, Octreotide therapeutic use, Receptors, Dopamine metabolism, Receptors, Somatostatin metabolism
- Abstract
Objectives: To evaluate somatostatin receptor 2A (SSTR2A) and dopamine receptor 2 (DR2) protein expression in somatotropinomas and to relate it to response to somatostatin analogues (SA)., Design and Patients: SSTR2A and DR2 expression was analyzed by immunohistochemistry in 88 somatotropinomas from patients submitted to either pre-surgical or adjuvant SA treatment. Tumors were scored according to percentage of immunostained cells: 0 (< 25%), 1 (25-50%), and 2 (> 50%). Relation between protein expression and response to SA was performed in 66 patients. Response to SA was assessed by percent IGF-I reduction, being considered as an IGF-I per cent reduction higher than 50%. Disease control was also assessed (GH < 1.0 ng/ml and normal IGF-I)., Results: SSTR2A and DR2 were expressed in 100% and 98% of tumors, respectively. Biochemical response and disease control rates were 48% and 32%, respectively. Median IGF-I percent reduction after 3 months of SA treatment was lower in the SSTR2A score 0 than in the scores 1 and 2 (p < 0.001, both), and after 6 months in the score 0 than in the score 1 (p = 0.001) and 2 (p < 0.001). Biochemical response and disease control were associated with SSTR2 expression (p < 0.001 and p = 0.004, respectively). A negative predictive value for biochemical response of 100% was found when a SSTR2A expression < 25%of immunostained cells cut-off point was considered. No relation was found between DR2 expression and biochemical response and disease control., Conclusion: SSTR2A and DR2 are highly expressed in somatotropinomas. Low SSTR2A, but not DR2, expression is a negative predictive factor to response to SA.
- Published
- 2013
- Full Text
- View/download PDF
41. Association of dengue hemorrhagic fever with multiple risk factors for pituitary apoplexy.
- Author
-
Wildemberg LE, Neto LV, Niemeyer P, Gasparetto EL, Chimelli L, and Gadelha MR
- Subjects
- Adult, Humans, Male, Risk Factors, Pituitary Apoplexy complications, Pituitary Apoplexy diagnosis, Severe Dengue complications
- Abstract
Objective: To describe pituitary apoplexy that developed during the course of dengue hemorrhagic fever., Methods: We describe the clinical findings, laboratory test results, imaging findings, and clinical course of the study patients., Results: Patient 1 was a 40-year-old man who developed clinical signs and symptoms of dengue, which was confirmed by serologic testing. He presented with thrombocytopenia and developed severe headache and vomiting. During hospitalization, acromegaly was suspected because of the characteristic disease phenotype. Magnetic resonance imaging confirmed the diagnosis of pituitary apoplexy. Subsequently, the biochemical diagnosis of acromegaly was confirmed, and the patient underwent transsphenoidal surgery. Histopathologic examination showed signs of recent bleeding. Patient 2 was a 38-year-old man with a macroprolactinoma, who had been treated with cabergoline for 10 weeks and had shown improvement on laboratory testing and imaging. The patient then presented with clinical symptoms of dengue (confirmed serologically) and thrombocytopenia. He developed bilateral hemianopsia, and magnetic resonance imaging showed enlargement of the pituitary adenoma with signs of intratumoral bleeding. The patient underwent transsphenoidal surgery, and histopathologic examination documented a pituitary adenoma diffusely infiltrated by blood cells., Conclusions: We describe dengue as a probable novel condition for pituitary apoplexy because it may be associated with multiple risk factors for pituitary infarction or bleeding. Physicians should suspect pituitary apoplexy in patients with dengue hemorrhagic fever who develop a rapid onset of severe headache and vision defects, even in those without known pituitary adenomas.
- Published
- 2012
- Full Text
- View/download PDF
42. Validation of immunohistochemistry for somatostatin receptor subtype 2A in human somatotropinomas: comparison between quantitative real time RT-PCR and immunohistochemistry.
- Author
-
Wildemberg LE, Vieira Neto L, Costa DF, Nasciutti LE, Takiya CM, Alves LM, and Gadelha MR
- Subjects
- Adult, Female, Humans, Immunoenzyme Techniques, Male, Middle Aged, RNA, Messenger genetics, Real-Time Polymerase Chain Reaction, Reverse Transcriptase Polymerase Chain Reaction, Adenoma genetics, Adenoma metabolism, Growth Hormone-Secreting Pituitary Adenoma genetics, Growth Hormone-Secreting Pituitary Adenoma metabolism, Receptors, Somatostatin genetics, Receptors, Somatostatin metabolism
- Abstract
Somatostatin receptors subtype 2 (SSTR2) expression in somatotropinomas is recognized as a predictor of response to the currently available somatostatin analogs and may be analyzed, mainly, by quantitative RT-PCR or immunohistochemistry (IHC). The former has the advantages of a higher sensitivity and of being quantitative, while the latter, although semi-quantitative, evaluates protein expression and is routinely used in the evaluation of pituitary adenomas. We aimed to evaluate the SSTR2A protein expression in somatotropinomas and to compare it to our previous data regarding mRNA expression, assessed by quantitative real time RTPCR. Thirteen somatotropinomas were analyzed by IHC and the tumors were scored according to percent of immunostained cells: 0 (<25%), 1 (25-50%) and 2 (>50%). SSTR2A immunostaining was present in all but one somatotropinoma, 4 (31%) tumors were classified as score 0, 4 (31%) as score 1, and 5 (38%) as score 2. Median SSTR2 mRNA content was significantly different among the three IHC scores (p=0.036) and was lower in the score 0 than in the score 2 (p=0.016). The finding that there is a positive correlation between RT-PCR and IHC indicates that IHC can be applied in order to assess the SSTR2A content in somatotropinomas.
- Published
- 2012
- Full Text
- View/download PDF
43. AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression.
- Author
-
Kasuki L, Vieira Neto L, Wildemberg LE, Colli LM, de Castro M, Takiya CM, and Gadelha MR
- Subjects
- Acromegaly drug therapy, Adenoma drug therapy, Adult, Antineoplastic Agents, Hormonal therapeutic use, Female, Growth Hormone-Secreting Pituitary Adenoma drug therapy, Humans, Male, Middle Aged, Octreotide therapeutic use, Pituitary Neoplasms, Young Adult, Acromegaly metabolism, Adenoma metabolism, Growth Hormone-Secreting Pituitary Adenoma metabolism, Intracellular Signaling Peptides and Proteins metabolism, Receptors, Somatostatin metabolism
- Published
- 2012
- Full Text
- View/download PDF
44. Sellar and suprasellar mixed germ cell tumor mimicking a pituitary adenoma.
- Author
-
Wildemberg LE, Vieira Neto L, Taboada GF, Moraes AB, Marcondes J, Conceição FL, Chimelli L, and Gadelha MR
- Subjects
- Adenoma pathology, Adult, Diagnosis, Differential, Humans, Male, Mixed Tumor, Malignant pathology, Neoplasms, Germ Cell and Embryonal pathology, Pituitary Neoplasms pathology, Adenoma diagnosis, Mixed Tumor, Malignant diagnosis, Neoplasms, Germ Cell and Embryonal diagnosis, Pituitary Neoplasms diagnosis, Sella Turcica pathology
- Abstract
Germ cell tumors (GCT) are a heterogeneous group of lesions whose origin is not well established. Several cases of primary intrasellar germinomas have been reported, however non-germinomatous GCT have rarely been described. We report the case of a young adult male patient with a mixed GCT that presented with a sellar tumor with suprasellar extension. The patient seeked medical attention because of seizures and magnetic resonance imaging evidenced a tumor of the sellar region. Hyperprolactinemia was also present and dopamine agonist therapy was started. As there was a rapid tumor growth and the patient had concomitant central diabetes insipidus and elevated testosterone levels, a GCT was suspected and confirmed by elevated serum concentration of β-human chorionic gonadotrophin. Patient underwent surgical resection of the tumor and histopathological examination confirmed the diagnosis of a mixed GCT. Chemotherapy was initiated, followed by conventional radiotherapy. In conclusion, although pituitary adenomas respond for the vast majority of sellar tumors, concomitant symptoms such as central diabetes insipidus and rapid tumor growth should raise the suspicion of a diverse diagnosis. The present report intend not only to show a rare case of sellar and suprasellar mixed GCT but also to remind clinicians that if laboratory findings do not fit into patient's diagnosis (such as high testosterone levels in our patient), then the diagnosis should be reviewed.
- Published
- 2011
- Full Text
- View/download PDF
45. Hematologic neoplasias and acromegaly.
- Author
-
Barbosa FR, Vieira Neto L, Lima GA, Wildemberg LE, Portugal R, and Gadelha MR
- Subjects
- Female, Hematologic Neoplasms diagnosis, Humans, Middle Aged, Multiple Myeloma complications, Multiple Myeloma diagnosis, Waldenstrom Macroglobulinemia complications, Waldenstrom Macroglobulinemia diagnosis, Acromegaly complications, Hematologic Neoplasms complications
- Abstract
We report a 59-year-old acromegalic woman, who presented with generalized bone pain, weakness, fatigue and foamy urine, who was found to have multiple myeloma (MM); and a 60-year-old acromegalic woman with dizziness, vomiting and abdominal pain, high blood pressure and splenomegaly that was posteriorly diagnosed as having Waldenstrom's macroglobulinemia (WM). Acromegaly is an uncommon disease and epidemiological studies have provided increasingly debated evidence that elevated IGF-I levels might enhance the neoplastic risk, and that cancers constitute the third leading cause of mortality in acromegaly. It is known that GH and IGF-I can activate B cell lymphocytes, and that IGF-I receptor is universally expressed in MM cells. Although the complication of acromegaly with WM or MM in patients has rarely been reported until now, we described two case reports of acromegalic patients with those hematological neoplasias, which allow a discussion about this controversial issue.
- Published
- 2011
- Full Text
- View/download PDF
46. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53.
- Author
-
Kasuki Jomori de Pinho L, Vieira Neto L, Armondi Wildemberg LE, Gasparetto EL, Marcondes J, de Almeida Nunes B, Takiya CM, and Gadelha MR
- Subjects
- Adenoma diagnosis, Adenoma pathology, Adult, Aged, Aged, 80 and over, Cell Proliferation, Female, Growth Hormone metabolism, Humans, Male, Middle Aged, Neoplasm Invasiveness, Pituitary Neoplasms diagnosis, Pituitary Neoplasms pathology, Predictive Value of Tests, ROC Curve, Retrospective Studies, Sensitivity and Specificity, Adenoma metabolism, Biomarkers, Tumor metabolism, Intracellular Signaling Peptides and Proteins metabolism, Ki-67 Antigen metabolism, Pituitary Neoplasms metabolism, Tumor Suppressor Protein p53 metabolism
- Abstract
Background: Some pituitary adenomas exhibit fast growth and invade surrounding structures. To date, there is no robust marker to predict invasiveness., Aim: To evaluate Ki-67, p53 and aryl hydrocarbon receptor-interacting protein (AIP) expression and compare these between invasive and noninvasive somatotropinomas and nonfunctioning pituitary adenomas (NFPAs)., Methods: Protein expression was determined by immunohistochemistry. Tumors were classified according to percentage of immunolabeled nuclei for Ki-67 and p53. AIP immunopositivity was graded according to a score encompassing pattern and intensity. Invasiveness was defined according to radiological and surgical criteria., Results: Thirty-eight sporadic somatotropinomas were studied. Median Ki-67 labeling index in invasive and noninvasive tumors was 1.6 (range 0-20.6) and 0.26 (0-2.2), respectively (p = 0.01). With a 2.3% cut-off point obtained by ROC curve analysis, invasive adenomas were distinguished with 100% specificity, 39% sensitivity, and 63% accuracy. Low AIP expression was also correlated with tumor invasiveness (p = 0.001), with sensitivity, specificity and accuracy of 78, 80, and 79%, respectively. Expression of p53 was not different among tumors. Twenty-nine NFPAs were studied, with no significant difference between Ki-67, p53 and AIP expression in invasive and noninvasive tumors. High AIP expression was more frequent in NFPAs, with Ki-67 >3% (p = 0.051), especially when only gonadotrope cell adenomas (n = 25) were considered (p = 0.012)., Conclusions: These data suggest, for the first time, that AIP is a better marker of invasiveness in somatotropinomas than Ki-67 and p53. In addition, low AIP expression is observed in invasive somatotropinomas, in contrast with high AIP expression in NFPAs (mainly gonadotrope cell tumors) with high proliferative indices., (Copyright © 2010 S. Karger AG, Basel.)
- Published
- 2011
- Full Text
- View/download PDF
47. Familial isolated pituitary adenomas experience at a single center: clinical importance of AIP mutation screening.
- Author
-
Pinho LK, Vieira Neto L, Wildemberg LE, Moraes AB, Takiya CM, Frohman LA, Korbonits M, and Gadelha MR
- Subjects
- Acromegaly diagnosis, Adenoma diagnosis, Adult, Female, Humans, Male, Middle Aged, Pituitary Neoplasms diagnosis, Prolactinoma diagnosis, Prolactinoma genetics, Young Adult, Adenoma genetics, Family, Intracellular Signaling Peptides and Proteins genetics, Mutation, Pituitary Neoplasms genetics
- Abstract
We present four FIPA kindred discussing clinical and molecular data and emphasizing the differences regarding AIP status, as well as the importance of genetic screening. Family 1 consists of five patients harboring somatotropinomas with germline E24X mutation in AIP. In one of the patients, acromegaly was diagnosed through active screening, being cured by surgery. Families 2 and 3 are composed of two patients with non-functioning pituitary adenomas. Family 4 comprises patients harboring a prolactinoma and a somatotropinoma. No mutations in AIP were found in these families. No patient in Family 1 was controlled with octreotide treatment, while the acromegalic patient in Family 4 was controlled with octreotide LAR. In conclusion, FIPA is a heterogeneous condition, which may be associated with AIP mutation. Genomic and clinical screening is recommended in families with two or more members harboring pituitary adenomas, allowing early diagnosis and better outcome.
- Published
- 2010
- Full Text
- View/download PDF
48. Utility of [(18)F] fluoro-2-deoxy-D: -glucose positron emission tomography in the localization of ectopic ACTH-secreting tumors.
- Author
-
Moraes AB, Taboada GF, Carneiro MP, Neto LV, Wildemberg LE, Madi K, Domingues RC, and Gadelha MR
- Subjects
- Adult, Carcinoid Tumor diagnosis, Carcinoid Tumor metabolism, Carcinoma, Small Cell diagnosis, Carcinoma, Small Cell metabolism, Female, Humans, Immunohistochemistry, Magnetic Resonance Imaging, Male, Middle Aged, Fluorodeoxyglucose F18, Neoplasms diagnosis, Neoplasms metabolism, Positron-Emission Tomography methods
- Abstract
Ectopically ACTH producing tumors may be difficult to localize by conventional radiology and functional imaging may be helpful. Case 1: 31-year-old man was diagnosed with ectopic ACTH-dependent Cushing's syndrome (ECS). Thorax CT revealed a 1.3 cm nodular opacity in upper left lobe, suggestive of residual lesion. [(18)F] fluoro-2-deoxy-D: -glucose ([(18)F] FDG) positron emission tomography ([(18)F] FDG PET) scan revealed mild glycolytic metabolic activity. Pathological examination confirmed an ACTH-positive carcinoid tumor. Case 2: 53-year-old woman presented with very rapid onset ECS. Pituitary MRI was normal. Thorax CT revealed no tumoral lesion. Abdominal and pelvic MRI showed images suggestive of hepatic and iliac, femoral and lumbar secondary implants. [(18)F] FDG PET scan revealed intense uptake in uterus, especially cervix, suggesting this to be the primary tumor site. These cases illustrate the role of [(18)F] FDG PET in the investigation of an ECS where conventional imaging studies were not elucidative in the search for a responsible tumor.
- Published
- 2009
- Full Text
- View/download PDF
49. [Reversible dilated cardiomyopathy related to hyperthyroidism].
- Author
-
Wildemberg LE, Sousa LL, Fonseca LP, and Souza MV
- Subjects
- Adult, Cardiomyopathy, Dilated therapy, Heart Failure therapy, Humans, Hyperthyroidism therapy, Male, Ventricular Dysfunction etiology, Cardiomyopathy, Dilated etiology, Heart Failure etiology, Hyperthyroidism complications
- Abstract
Heart failure is one of the most known complications of hyperthyroidism, more commonly high-output heart failure, but some patients may develop dilated cardiomyopathy with low ejection fraction. We report a 35-year-old man, with hyperthyroidism, atrial fibrillation, and severe heart failure with 43% of ejection fraction. After the definitive treatment of the hyperthyroidism with radioiodine, heart failure was reverted, with symptomatic improvement and echocardiographic normalization including a normal ejection fraction (69%). There are several cases of reversion of heart failure due to hyperthyroidism treatment, but most of them with a high-output heart failure. Mechanisms by which hyperthyroidism can lead to heart failure and its treatment are discussed. We conclude that treatment of hyperthyroidism may reverse this thyroid related heart failure, even in severe cases with systolic dysfunction.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.